It is not approved by Health Canada for human consumption and is sold strictly for laboratory and research applications
Composition CJC-1295 (Without DAC): 5 mg Ipamorelin: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Comparative and combined pathway evaluation of GHRH analog + GHS agonist in in-vitro or ex-vivo models Assessment of assay development, including chromatographic separation of co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation COA pending third-party verification in progress Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability
Dutkowski, P., et al
Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al
Angiogenesis & microcirculation: studies on new blood-vessel formation and vascular support
This action also reduces endothelial damage during NSAID induction